Integra LifeSciences to Present At Canaccord Adams 27th Annual Global Growth Conference
PLAINSBORO, N.J., Jul 24, 2007 (PrimeNewswire via COMTEX News Network) --
Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at the Canaccord Adams 27th Annual Global Growth Conference at the InterContinental Boston Hotel in Boston at 8:00 AM ET on Thursday, August 9, 2007.
The presentation will be delivered by John B. Henneman III, Executive Vice President and Chief Administrative Officer of Integra. A live webcast of this presentation can be accessed through a link provided in the Investor Relations section of Integra's website at http://www.integra-LS.com. Additionally, a replay of the webcast will be available through Thursday, August 23, 2007.
The presentation will provide an overview of Integra's operations, with a focus on currently marketed products, sales distribution channels, and product pipeline, recent financial history, and Integra's overall business strategy for growth.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (http://www.Integra-LS.com).
Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
IART-G
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Integra LifeSciences Holdings Corp.
Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com
John Bostjancic, Vice President, Corporate Development
and Investor Relations
(609) 936-2239
jbostjancic@integra-LS.com
(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.
News Provided by COMTEX